CD274 and non-small cell lung carcinoma: A critical knowledge gap therefore persists regarding the true therapeutic value of pembrolizumab in patients with PD-L1-positive advanced NSCLC, particularly in light of evolving biomarker limitations and patient-related factors influencing treatment response [41,42].